Catalyst Biosciences has secured another big deal focused on its Alterase drug discovery engine, this time partnering with MedImmune, the global biologics unit of AstraZeneca plc, to develop drug candidates against two targets, one of which will address inflammatory and autoimmune diseases. (BioWorld Today) Read More
